JOHANSEN ODD-ERIK,KLEIN THOMAS,LUIPPOLD GERD,BROEDL ULI,VON EYNATTEN MAXIMILIAN
申请号：
NZ61854612
公开号：
NZ618546A
申请日:
2012.07.03
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed herein is the use of the SGLT-2 inhibitor 1-chloro-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene in the manufacture of a medicament for the treatment or prevention of renal hyperfiltrative injury wherein the patient has a glomerular filtration rate (GFR) equal to or greater than 140mL/min/1.73 m2, wherein the medicament comprises 10 mg or 25 mg of the SGLT2 inhibitor, and wherein the patient is an individual diagnosed or showing one or more of the following conditions: (a) diabetes mellitus (b) congenital or acquired obstructive uro/nephropathy (c) progressive chronic kidney disease (CKD) (d) acute renal failure (ARF) (e) renal transplant recipients (f) renal transplant donors or (g) unilateral total or partial nephrectomized patients. The medicament is often useful in patients diagnosed with metabolic disorders and related conditions, in particular diabetes mellitus and kidney disfunction.
